The enzyme nitroreductase, isolated from Escherichia coli a much higher concentration (500 M). We subsequently B, converts CB1954 ((5-aziridin-1-yl)-2,4-dinitro-benzgenerated transgenic mice to test the prodrug system in amide) into a cytotoxic DNA interstrand cross-linking agent.
Introduction
be activated by nitroreduction in E. coli in an analagous Prodrugs are substances which are not toxic, but can be manner to its bioactivation in Walker cells. A nitroreducactivated to produce cytotoxic derivatives. For the purtase enzyme (NTR) has been isolated from E. coli B. 7 The poses of anticancer therapy, this activation should be enzyme is an FMN-containing flavoprotein with molecuspecifically associated with tumour cells. The monofunclar mass of 24 kDa and requires either NADH or NADPH tional alkylating agent CB1954 (5-aziridin-1-yl)-2,4 as a cofactor. Indeed, it was found that E. coli nitroreducdinitrobenzamide) was synthesised in the late 1960s 1 and tase is capable of reducing CB1954, that it is a more active was found to be highly potent and selective against the enzyme (k cat = 360/min for CB1954 versus k cat = 4/min for Walker 256 rat tumour line.
2 DNA cross-link formation Walker cell DT diaphorase) and also has a lower K m for in affected cells was a result of the bioactivation of the NADH (6 versus 75 m). 8 Thus E. coli nitroreductase is drug by the enzyme DT diaphorase (NAD(P)H dehydropotentially a suitable candidate for cancer chemotherapy genase (quinone)) in the Walker cells which reduces the programmes such as antibody-directed enzyme prodrug 4-nitro group of CB1954. The product of this reaction is therapy (ADEPT), where a tumour-selective monoclonal a difunctional alkylating agent, 5-aziridin-1-yl-4-antibody is conjugated to an enzyme that is capable of hydroxylamino-2-nitrobenzamide. This molecule can not bioactivating a prodrug. 9 Isolation of the gene encoding cross-link DNA itself, but is further activated by a nonennitroreductase, nfnB (NTR) 10 also raises the possibility of zymatic reaction with thioesters (such as coenzyme A). 3 gene-directed enzyme prodrug therapy (GDEPT), where However, except for a few rat hepatoma and hepatocyte a gene is introduced into cells, and if expressed can acticell lines, other rat cells are not known to be sensitive to vate a prodrug. Expression can be directed to the tissue(s) CB1954, in agreement with their low levels of DT diaphoof interest by using an appropriate locus control region rase, and human cells, even those expressing significant (LCR), such as described for the human ␤-globin gene levels of the human DT diaphorase, are not sensitive due locus, 11 human CD2, 12 chicken lysozyme, 13 human to differences in the kinetics of CB1954 reduction by these S100␤ 14 and mouse MHC class II. 15 two forms of the enzyme. 4 Here, we describe the expression of NTR in eukaryotic Apart from Walker cells, sensitivity to CB1954 has also cells. Initially, the enzyme was expressed in a mouse been reported in bacteria. 5 The toxicity and mutagenicity fibroblast cell line. Expressing cells could be killed by the of CB1954 was greatly reduced in a nitroreductaseapplication of the prodrug to the culture. To show that the prodrug system works in vivo and exclusively on targeted tissues, we generated transgenic mice expressing (Figure 1a) . After selection for 7 days at 800 g/ml G418, 10 independent clones were picked and kept further at 400 g/ml G418.
The clones were analysed for expression at the RNA level. An S1 nuclease protection assay using a 3′ end probe showed a protected fragment of the expected size (213 bp) in all clones (see Figure 2a) . Knowing that there is a stable message, we performed indirect immunofluorescence using a rabbit polyclonal antinitroreductase antibody. By counting NTR positive cells in randomly chosen fields, it was estimated that none of the clones the gene. 16 are gross changes in morphology, including 10-to 20-fold CB1954 causes gross changes in morphology and enlargement of the cells, enlargement of nuclei, multiple eventual cell death in cells expressing nitroreductase nuclei and ultimately nuclear disintegration ( Figure 3 ). The fact that only a small percentage of cells were After 7 days of exposure to the prodrug, these cells disapexpressing NTR made quantitative analysis of the effect pear from the culture. All cells expressing nitroreductase of CB1954 impossible, so we used a qualitative approach.
were affected in this way, whereas nonexpressing cells in pCMV/NTR transfected L cells were exposed to the prothe same culture appeared to be normal. drug for various times, and prodrug concentrations
The effect of the prodrug on the cells was irreversible between 10 m and 500 m. Untransfected cells were not after 2 days of treatment, since returning these cells to affected by CB1954 below a concentration of 500 m, normal culture conditions did not lead to their recovery. whereas cells expressing nitroreductase started to show signs of toxicity at 10 m and were all affected at 20 m.
CD2/NTR transgenic mice express nitroreductase Effects of the prodrug on cells expressing nitroreductase specifically in T cells and thymocytes Five founder mice carrying the CD2/NTR construct ( Figure 1b) were obtained, and lines of each were established. Different tissues were tested for expression of the transgene by S1 nuclease protection analysis (data not shown). The transgene expression, when detected (two out of five lines) was confined to the expected cell types: T cells and thymocytes (see Figure 2a) . Further experiments were done on line 14 which has three copies of the transgene and the highest level of nitroreductase enzyme as determined by Western blotting (data not shown). FACS analysis on single cell suspensions from thymus showed that all CD2-positive cells was detected only in B220
− , IgM − , CD2 + and CD3 + cells.
Figure 2 (b) FACS analysis of NTR expression in transgenic mouse thymus. (i) Single-staining with anti-nitroreductase polyclonal antibody on thymocytes from: CD2/NTR transgenic mouse, secondary antibody only (dotted line); non-transgenic mouse, primary and secondary antibodies (dashed line); CD2/NTR transgenic mouse, primary and secondary antibodies (solid line). (ii) Double staining of CD2/NTR transgenic mouse thymocytes with antinitroductase (FITC) and anti-CD2 (phycoerythrin, PE) antibodies.

CD2/NTR transgenic mice show depletion of T cells (data not shown)
. Surprisingly, in the spleen the B to T cell ratio is not significantly changed, implying that B upon CB1954 treatment In a pilot experiment, nontransgenic mice (FVB) were cells are also killed.
The red blood cell count was normal and comparable injected i.p. with 10, 20 and 50 mg/kg/day CB1954 (dissolved in 20% DMSO in PBS) for 5 consecutive days.
to controls. The white blood cell count was slightly decreased, as expected. These doses were chosen after considering the toxicology and pharmacokinetic data determined for BALB/c and In another experiment, animals were killed 5 days after the last prodrug or solvent treatment instead of 3 h later. C3H/He mice. [17] [18] [19] All animals receiving the highest dose were very sick with multiple organs affected. In partiIt was seen that thymuses and spleens returned to their normal size during this prodrug-free period (data not cular the intestine (containing NTR-positive bacteria) was severely affected. The lowest dose had absolutely no shown). We therefore conclude that the progenitor cells which do not express CD2 (or the transgene) have not effect, whereas the middle dose caused a slight reduction in weight compared to nontreated animals but no other been affected and are able to repopulate the spleen and thymus. visible problems. Hence we chose this dose of 20 mg/kg/day to test the transgenic animals.
Three-week-old transgenic and wild-type mice were Discussion injected i.p. with CB1954, solvent only (10% DMSO in PBS), or not injected at all. Two nontreated groups con-CB1954 is converted by nitroreduction from a monofunctional to a difunctional agent. Induced DNA interstrand sisted of seven mice each, two solvent-treated groups consisted of nine mice each and two CB1954-treated cross-links are formed with very high frequency, and can contribute up to 70% of total lesions. 20 Interstrand or groups consisted of 13 mice each. Animals received 20 mg/kg of CB1954 per day for 5 consecutive days.
intrastrand cross-link formations are generally accepted as the most toxic lesions, inhibiting DNA function and Three hours after the last injection mice were killed, different organs macroscopically examined and red and eventually resulting in cell death. Our results showed that eukaryotic cells are able to white blood cell counts determined.
Visually, there was an obvious difference in the size of express the E. coli nitroreductase gene and judging by the end result (cell death), are capable of reducing the subtwo organs: thymus and spleen. Thymuses and spleens from CB1954-treated transgenics were much smaller than strate (CB1954), inducing DNA interstrand crosslink formation leading to cell death. Changes in morphology of in all other controls. Single cell suspensions were made from these two organs and the total number of cells counthe cells expressing the enzyme upon CB1954 exposure can be explained by a block in DNA synthesis coinciding ted. CB1954-treated transgenic thymuses and spleens had 14-16% of the cell numbers present in controls with a cessation of cell division, although RNA and protein synthesis continue, as evidenced by a continued (Figure 4a ).
An assay for apoptosis was performed on single cell increase in cell mass. A similar phenomenon was observed in E. coli B s−1 .
5 suspensions from the thymus using the In Situ Cell Death Detection kit, Fluorescein (Boehringer Mannheim, Our data show that some L cells expressing nitroreductase were able to survive exposure to 10 m but not Mannheim, Germany). A significantly higher percentage of apoptotic cells was seen in CB1954-treated transgenic 20 m CB1954, suggesting that at a certain concentration they were no longer capable of repairing the DNA cells as compared to control groups: 15% versus 0.5-4% (Figure 4b ). FACS analysis on thymocytes showed that adducts formed as a result of the bioactivation of the prodrug. Cells failed to replicate their DNA and proceed there is no change in the normal ratio between CD4CD8 double positive, CD4CD8 double negative and single through successive cycles of cell division. It has been shown that CB1954 forms DNA interstrand CD4 and CD8 positive cells in treated transgenic mice 
(a, c, e, g) Indirect immunofluorescence using a rabbit polyclonal antibody against nitroreductase, with FITC-conjugated goat-anti rabbit Ig as secondary antibody. (b, d, f, h) Nuclear staining of the same fields of cells with 4′-6-diamidino-2-phenylindole (DAPI). (a, b) L cells transfected with pCMV/NTR and grown in the absence of CB1954. (c, d) Untransfected L cells grown in the presence of 50 m CB1954 for 5 days. (e, f) pCMV/NTR transfected L cells grown in presence of 50 m CB1954 for 5 days. (g, h) pCMV/NTR transfected L cells grown in the presence of 50 m CB1954 for 2 days and then in prodrug-free medium for a further 3 days.
cross-links in Walker cells but not in the insensitive Chiexplained by the very small percentage of cells expressing the enzyme (5-10%), in agreement with the results of nese hamster V79 cells. Co-culturing V79 cells with Walker cells in the presence of CB1954 results in sensitisBridgewater et al 22 who found that 30-50% of NTR positive cells are required for 90% overall cell killing, using ation of the V79 cells towards CB1954. 21 The toxic metabolite was shown to be soluble and diffusible by its ability transduced NIH 3T3 cells. The relatively short half-life of the active metabolite, a lack of intimate cellular contact to be cytotoxic, and to cross-link DNA in V79 cells. We were expecting to see a similar effect in cell culture between expressing and nonexpressing cells or L cells being intrinsically more resistant to CB1954 than V79 experiments. The effect of the prodrug on NTR nonexpressing cells due to the presence of NTR expressing cells cells are other possibilities. In order to assess the proposed therapy system in vivo in the very same culture was not seen. This could be an animal model was tested. The aim was to direct the expression of NTR to a specific tissue and to achieve killing of the chosen target. We directed NTR expression to T cells by the use of human CD2 LCR elements, previously shown to be sufficient for T cell-specific, copy numberdependent, integration site-independent expression in transgenic mice. 23 The transgenic mice which were generated express the nitroreductase in T cells, as predicted. However, it was not expressed in all of the transgenic lines, which may indicate that the 2.1 kb 3′ LCR fragment of the CD2 gene is not sufficient for integration-independent expression of the transgene. Recently, an improved version of a human CD2 mini-gene-based vector has been made for T cell-specific expression in transgenic mice which in addition to the 3′ LCR includes 5′ sequences and the first intron of the CD2 gene.
24 CD2 is one of the earliest markers to appear on the surface of developing thymocytes and in man it is present only on thymocytes and circulating T cells. In the mouse, however, it is present on both T and B cells. As we have used human CD2 locus control elements, expression of the transgene is detected only in T cells.
Toxicity studies on CB1954 were carried out to establish acceptable doses for single and multiple administration in BALB/c and C3H/He mouse strains. 18 Our pilot experiments indicated that the FVB mouse strain used in this study is somewhere between BALB/c and C3H/He in its sensitivity towards CB1954. We used twothirds of the LD 10 for a multiple-dose regimen which was established in BALB/c mice (31 mg/kg/day). Weight loss due to enteritis would be the first sign of toxicity, as previously described in rats 2 and in mice. 18 More than half of our experimental animals started to lose weight on day 4 of the experiment, and when killed on day 5 these showed a loss of 5 to 15%, suggesting that the threshold of toxicity was reached. The toxic effect is seen in the spleen of wild-type mice treated with the prodrug where, although the appearance is normal, there is a slight reduction in cell numbers when compared with untreated mice. Since the prodrug was administered intraperitoneally, the spleen was accessible almost immediately after the injection and will have experienced a much higher local concentration of prodrug than the thymus. Nevertheless, our results clearly demonstrate selective killing in lymphoid organs of CD2/NTR transgenic mice. As mentioned before, in fibroblast transfection studies it has been shown that 30-50% expressing cells are enough to kill 90% of all cells. 22 In the spleen, T cells contribute about 40% of the total number of cells, By using transgenic mice we have shown that only cells expressing the NTR enzyme are able to convert the nontoxic prodrug CB1954 to a cytotoxic drug, resulting in highly specific killing of T cells and thymocytes, while other tissues are unaffected. The apparent killing of NTR 98 negative B cells in the spleen may result from the high expression at the RNA and protein level. For further growth the G418 concentration was redued to 400 g/ml. proportion of expressing cells and the proximity of expressing and nonexpressing cells in this organ. The specific killing by nitroreductase/CB1954 is in contrast CB1954 assay with cytotoxic agents used in chemotherapy, which in Cells were seeded at 1 × 10 5 cells per dish in 10 cm dishes addition to killing tumour cells also affect normal tissues.
containing sterile glass coverslips, in triplicate. CB1954 Nitroreductase is therefore an excellent candidate for was dissolved in DMSO (100 mm stock) and added to the gene therapy against tumours. GDEPT has a number of cells at a final concentration of 0, 10, 20, 50, 100, 250 and advantages over ADEPT (where the enzyme itself is 500 m in DMEM medium. Cells were observed for a delivered to cells). The enzyme requires a cofactor period of 7 days. As a control untransfected L cells were (NADH or NADPH) which is present only inside the cell, used under the same conditions. After 2 days a medium being rapidly oxidixed and degraded by serum change was performed and half the cultures received the enzymes.
26 Therefore the enzyme needs to be present original concentration of the prodrug and the other half inside the cell before it can activate the prodrug. Also, were grown in prodrug-free medium. Coverslips with specificity can be introduced both by targeted delivery of cells attached were removed from the culture at day 5 the gene to the required tissue, and by using tissue-speand immunocytochemistry was performed. cific elements (LCRs) to drive expression of the enzyme only in the target cells.
Immunofluorescence The rabbit polyclonal anti-nitroreductase antibody was kindly provided by R Melton and N Michael, Porton vale, CA, USA). For detection of cell surface markers the following monoclonal antibodies were used on unfixed containing 50 g of the plasmid pCMV/NTR linearised with ScaI was mixed with 3 ml of OPTIMEM-1 containing cells: anti CD2-PE (PharMingen), anti-CD3-FITC (PharMingen), anti-CD4-PE (Becton Dickinson, anti-CD8-100 l of Lipofectin (GibcoBRL) and added to the cells. Five hours later, 3 ml of DMEM/20% FCS was added to biotin, 27 anti-B220-cychrome (PharMingen), anti-IgMbiotin (PharMingen). Cells were incubated for 30 min on each dish. The next day, the medium was removed and replaced with DMEM/10% FCS containing G418 at a conice, washed and incubated where appropriate for 30 min with secondary antibodies (tricolor or PE conjugated centration of 800 g/ml. After 7 days of selection several independent clones were picked and analysed for streptavidin; Caltag Laboratories, Burlingame, CA, USA 10 g total RNA and 10-20 ng of probe in a reaction vol-6 Venitt S, Crofton-Sleigh C. The toxicity and mutagenicity of the ume of 20 l. After denaturation at 90°C for 5 min,
Materials and methods
Down
anti-tumour drug 5-aziridino-2,4-dinitrobenzamide (CB1954) is hybridisation was performed at 53°C for at least 16 h.
greatly reduced in a nitroreductase deficient strain of E. coli.
